Karyopharm Therapeutics (KPTI) EPS (Basic) Growth (1y) (2013 - 2026)
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) EPS (Basic) Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.02 Bn | 620.27 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 445.75 Bn | 439.18 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 357.52 Bn | 350.38 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 267.31 Bn | 259.62 Bn | 11.24 Bn | -15.94% |
| 5 | Pfizer | 156.58 Bn | 144.88 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.14 Bn | 44.75 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 43.04 Bn | 43.04 Bn | - | - |
| 8 | Incyte | 24.61 Bn | 20.07 Bn | 1.57 Bn | 39.99% |
| 9 | United Therapeutics | 21.30 Bn | 18.64 Bn | 683.80 Mn | 13.91% |
| 10 | Karyopharm Therapeutics | 46.59 Mn | -18.51 Mn | 32.35 Mn | 46.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 46.41% |
| Dec 31, 2025 | -46.86% |
| Sep 30, 2025 | 0.70% |
| Jun 30, 2025 | -246.56% |
| Mar 31, 2025 | 42.93% |
| Dec 31, 2024 | 31.27% |
| Sep 30, 2024 | 14.94% |
| Jun 30, 2024 | 168.81% |
| Mar 31, 2024 | -7.61% |
| Dec 31, 2023 | 23.50% |
| Sep 30, 2023 | 33.40% |
| Jun 30, 2023 | 53.62% |
| Mar 31, 2023 | 43.65% |
| Dec 31, 2022 | -193.63% |
| Sep 30, 2022 | 34.04% |
| Jun 30, 2022 | 13.57% |
| Mar 31, 2022 | 30.73% |
| Dec 31, 2021 | 185.34% |
| Sep 30, 2021 | 5.71% |
| Jun 30, 2021 | -12.42% |